The prostate-specific antigen (PSA) test, which became available in the late 1980s, offers a simple and affordable way to find asymptomatic men, who may be harboring an earlier stage of prostate cancer, thus increasing the likelihood of cure, and ultimately lowering prostate cancer-specific mortality (2, 3). Here, KLK3 is linked to prostate carcinoma.